Clinical Trials in Hirosaki, Aomori

9 recruiting

Showing 19 of 9 trials

Recruiting
Phase 3

Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

Non-small Cell Lung CancerNSCLC
Merck Sharp & Dohme LLC851 enrolled207 locationsNCT06422143
Recruiting
Phase 3

Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

Non-small Cell Lung Cancer (NSCLC)
Merck Sharp & Dohme LLC614 enrolled218 locationsNCT06170788
Recruiting
Phase 3

Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

Interstitial Lung DiseasePulmonary Hypertension
Insmed Incorporated344 enrolled96 locationsNCT07179380
Recruiting
Phase 3

A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)

Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC868 enrolled229 locationsNCT06077760
Recruiting
Phase 3

A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC675 enrolled149 locationsNCT07190248
Recruiting

Study to Assess Change in Disease Activity of Risankizumab Treatment in Japanese Participants With Moderate to Severe Ulcerative Colitis

Ulcerative Colitis
AbbVie200 enrolled28 locationsNCT07136116
Recruiting

Fabhalta Capsules Specified Drug-use Survey

C3 Glomerulopathy
Novartis Pharmaceuticals50 enrolled26 locationsNCT07156149
Recruiting
Phase 3

A Study of Vortioxetine in Japanese Pediatric Patients With Major Depressive Disorder

Major Depressive Disorder
Takeda180 enrolled30 locationsNCT07204314
Recruiting
Phase 3

Early Treatment With a Sodium-glucose Co-transporter 2 Inhibitor in High-risk Patients With Acute Heart Failure

Acute Heart Failure
Juntendo University444 enrolled69 locationsNCT05392764